AI will transform biotech investing. But piloting SaaS tools or hiring a few interns will not result in transformation. The potential of AI is not to save a few hours at the edges of your workflow. The potential of AI is to be your edge.
Most funds' experience with AI adoption looks something like this:
Most funds give up after the initial effort stalls. If they never get their hands dirty, they never understand the potential. But once you push through and build something real, everything changes—you see what's actually possible.
AI will transform investing. But unlike in coding, the winners won't be using third-party SaaS tools—they'll be the investors who build their own.
a16z didn't rent a platform. Jim Simons didn't buy Renaissance's algorithms from a vendor. Category-defining funds build their platforms. The AI-native biotech fund will too.
Right now, the field is wide open. A small team can still build industry-leading AI tools for biotech VC. But this window won't stay open. In a few years, the winners will have moats that others can't breach. The line between winners and losers will be drawn. And it will be increasingly hard to cross.
The good news: you don't need massive infrastructure to win. You don't need a team of data scientists, your own foundation model, or to become an engineering shop. You just need a tight feedback loop: investors who know what problems to solve, paired with a small team that rapidly executes on those ideas. Build a small amount of high-quality AI capability, and let it compound.
We help you build AI tools that compound your edge. Tools that you design and control.
Describe a tool or workflow you wish you had. We live-code a working prototype during the call.
We build the production version. This could be clinical data extraction, automated landscape mapping, custom diligence frameworks, portfolio monitoring, deal flow screening, or whatever you've been wishing existed.
We train you and your team to maintain and extend what we've built. You become the AI expert at your fund.
This isn't about automating busy work. It's about building capabilities that compound over time.
Custom tools designed for your exact investment process, not off-the-shelf SaaS products built for everyone.
No 6-month hiring process. No $200K+ salary. No risk they don't deliver. You get expert execution immediately, with deep biotech domain knowledge.
This positions you as the person who figured out AI at your fund, and as a leader in the industry's transition to the AI age.
Book a 30-minute demo call. Bring an idea for a tool you wish you had. We'll live-code it and show you what's possible.
Book Demo Call